iPS Cells & Regenerative Medicine– category –
-
Health Canada Accepts Vertex Pharmaceuticals’ New Drug Submission for Suzetrigine, a Novel NaV1.8 Inhibitor, for Moderate-to-Severe Acute Pain in Adults
BioSpace (via CNW) Canada Overview Vertex Pharmaceuticals announced that Health Canada has accepted its New Drug Submission (NDS) for suzetrigine, a novel oral NaV1.8 selective pain signal inhibitor, for the treatment of moderate-to-seve... -
Intellia Therapeutics Bolsters Market Value with Soaring Stock Price and Improved Financials Amid Positive CRISPR Gene Editing Regulatory Progress
Fintel USA Overview Intellia Therapeutics saw its stock price climb to $12.60 per share, marking a 35.12% year-over-year increase by May 2026, boosting its market capitalization to $1.91 billion. The company also improved its net loss in... -
UCLH Pioneering Gene Editing Therapy Successfully Lowers ‘Bad’ Cholesterol (LDL-C) with Single Dose in Encouraging Early Clinical Trial
University College London Hospitals NHS Foundation Trust UK Overview An early-stage clinical trial at University College London Hospitals (UCLH) has shown promising results where a single dose of gene editing therapy significantly lowere... -
3D-Printed Culture System Accelerates Transplantable Gut Organoid Growth Twofold, Generating Functional Neurons Autonomously
Drug Target Review USA Overview Researchers at Cincinnati Children's Hospital have developed a 3D-printed closed culture system (CCS) that doubles the growth rate of transplantable gut organoids. This novel system produces nearly tenfold... -
Sana Biotechnology Reports 14-Month Positive Clinical Results for Immunosuppression-Free iPSC-Derived Islet Cell Transplant in Type 1 Diabetes
Simply Wall St (via Nasdaq:SANA) USA Overview Sana Biotechnology announced continued positive clinical results from its study of iPSC-derived islet cell transplantation (UP421) for Type 1 diabetes, spanning 14 months without immunosuppre... -
FUJIFILM Cellular Dynamics Quadruples iPSC Manufacturing Capacity with $200M New Facility in Wisconsin, Meeting Soaring Cell Therapy Demand
Manufacturing Dive USA Overview FUJIFILM Cellular Dynamics (FCDI) has inaugurated a new headquarters and iPSC development and manufacturing facility in Madison, Wisconsin, backed by a $200 million investment. This 170,000 square-foot exp... -
CRISPR Gene Editing Evolves with Cas12a2 to Shred Sick Cell DNA, Expanding Therapeutic Horizons for Cancer and Viral Infections
Top Doctor Magazine USA Overview The CRISPR gene editing landscape is rapidly evolving in 2026, driven by the FDA approval of Cas9-based CASGEVY and the discovery of the novel Cas12a2 protein's ability to 'shred' diseased cell DNA. Unlik... -
iPS Cells & Regenerative Medicine Weekly Report May 24, 2026
🎙 Podcast May 24, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260524.mp3Download -
Vertex Pharmaceuticals Secures CASGEVY Reimbursement Agreement in Germany for Sickle Cell Disease and Beta Thalassemia
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced a reimbursement agreement in Germany for CASGEVY (exa-cel), a groundbreaking gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassem... -
iPSC-Derived Retinal Sheet Transplantation for Retinitis Pigmentosa: Clinical Trial Validates Long-Term Safety and Engraftment
臨床研究等提出・公開システム (jRCT) Japan Overview A pioneering clinical study (jRCTa050200027) conducted by Kobe City Eye Center Hospital has concluded, affirming the long-term safety and engraftment of allogeneic iPSC-derived retinal s...
